Huvitz휴비츠

Huvitz's profit has shrunk sharply since 2023, and the shares are down 22% over the past year.

Huvitz, a Korean maker of eye care medical devices, still generates about ₩121B in trailing revenue at a 4.3% operating margin. Net income has fallen to about ₩1.4B over the last twelve months, after a large net loss in 2025, and the shares trade near ₩6,890, closer to the 52-week low than the high. Filings show recent share buyback, trust and merger-related activity, but the data does not explain these in detail.

What stands out

• Trailing twelve-month revenue is ₩121B, roughly flat with 2025 and 2024, so top-line growth has stalled at around 0.1% a year.
• Operating margin has fallen from 17.4% in 2022 to 4.3% on a trailing basis, and net margin is just 1.2%.
• The company reported a net loss of about ₩5.0B for 2025 after profits in earlier years, with ROE turning negative at -4.5%.
• Cash of about ₩4.3B and minimal borrowings (about ₩4.5M) stand out, while liabilities are about 101% of equity.
• The DCF fair value model gives a base value of ₩17,642, above the current price, but the bear case is ₩10,887 and the bull case ₩28,813; the model assumptions are not explained in the data, and this is not a forecast.

What to watch

• The full-year 2026 results and the next quarterly report, to see whether margins hold after the sharp decline.
• Details of the pending merger decision, the share cancellation decisions and the buyback trust arrangements, which the data does not explain.
• Foreign ownership has dropped from 4% to 3% over 60 days, and the trailing P/E of about 52 is high relative to earnings, so earnings recovery is a key uncertainty.